Enhance Your Inhalation Formulation to Overcome Biological Barriers for
Targeted Delivery to the Lungs
With exciting developments in pioneering inhaled drug products from Moderna, Vertex, ReCode Therapeutics, and Pieris Pharmaceuticals, now is the time to go full speed ahead on your efforts into inhaled formulation and delivery optimization. Despite the inhalation drug delivery market being expected to reach $18.6 billion by 2029, achieving cell-specific delivery, and optimized stability remain vital challenges.
This June, the hotly anticipated Next Gen Inhalation Delivery Summit debuted, where we united 60+ senior leaders at this definitive meeting dedicated to the inhalation community. Whether your work in COPD, asthma, IPF, lung cancer or infectious disease, this comprehensive forum offers the solution to capitalize on the common goal of targeted lung delivery.
The conversation in Boston this June unpicked:
- Overcoming pulmonary biological barriers to minimize dosage and maximize therapeutic benefit
- Advancing your inhalation formulation techniques for improved stability and longer shelf-lives
- Ensuring device-formulation compatibility with patient compliance and patient convenience
With key speakers from the likes of Janssen, Avalyn Pharma, and Pieris, exciting content, and networking opportunities, you cannot afford to miss out!